Health Economics and Outcomes Research

Commercial payers are spending almost twice as much on chemotherapy administered in hospital outpatient departments compared with therapy administered in physician offices.
FDA-approved CAR T-cell therapies may be associated with high costs, but the therapies are priced in alignment with their clinical value, according to an Institute for Clinical and Economic Review evidence report.
A systematic review presented at the 2018 ASCO Cancer Survivorship Symposium determined whether survivorship care plans have a positive impact on health outcomes and health care delivery.
Researchers presenting at the 2018 ASCO Genitourinary Cancers Symposium compared the costs associated with two different approaches to management of low-risk prostate cancer and gave a recommendation toward a value-based care model.
A cost-effectiveness analysis presented at the 2018 Genitourinary Cancers Symposium examined the use of a hydrogel rectal spacer in patients with prostate cancer undergoing intensity-modulated radiation therapy.
Researchers compared the overall survival, cancer-specific survival, and associated costs of trimodal therapy versus radical cystectomy for patients with localized muscle-invasive bladder cancer.
The addition of docetaxel to first-line long-term hormone therapy in prostate cancer improves overall health-related quality of life, reduces the need for further therapy, and is cost effective.
In a recent study, researchers evaluated the role of autologous stem cell transplantation in patients with multiple myeloma in the context of novel agents.
Immunotherapy treatment past progression for patients with advanced lung cancer may account for 29% of total treatment costs, without clear value for most patients, according to a presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium.
A comparative effectiveness study examined the costs associated with short-course radiation therapy versus long-course chemoradiation for locally advanced rectal adenocarcinoma.